Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05381311 · ClinicalTrials.gov registry record
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
A clinical trial, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- 1,020
- Enrollment target
NCT05381311: Completed study, sponsored by Astellas Pharma Global Development.
NCT05381311 is a clinical trial that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 1,020 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05381311 has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- 1,020 participants
- Enrollment target
Study Summary
The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.
Primary Outcome
Log-odds indicate participants' relative preferences for treatments with each attribute level in the study, all else equal.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2022-12-11 |
What the finished NCT05381311 record still lists
NCT05381311 is an observational study that tracks outcomes without assigning an intervention. Its 1,020 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05381311 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05381311 about?
NCT05381311 is a clinical study titled "Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study". The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This s...
What is the current status of trial NCT05381311?
This trial is currently completed. The enrollment target is 1,020 participants. The study started on 2021-09-03. Estimated completion is 2022-12-11.
Who is sponsoring clinical trial NCT05381311?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI